JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB169639

Anti-PARG antibody

Be the first to review this product! Submit a review

|

(7 Publications)

Mouse Polyclonal PARG antibody. Suitable for WB, ICC/IF and reacts with Human samples. Cited in 7 publications. Immunogen corresponding to Recombinant Full Length Protein corresponding to Human Poly(ADP-ribose) glycohydrolase.

View Alternative Names

Poly(ADP-ribose) glycohydrolase, PARG

3 Images
Immunocytochemistry/ Immunofluorescence - Anti-PARG antibody (AB169639)
  • ICC/IF

Unknown

Immunocytochemistry/ Immunofluorescence - Anti-PARG antibody (AB169639)

Immunofluorescence analysis of paraformaldehyde-fixed HeLa cells, labeling PARG using ab169639 at 10 µg/ml.

Western blot - Anti-PARG antibody (AB169639)
  • WB

Unknown

Western blot - Anti-PARG antibody (AB169639)

All lanes:

Western blot - Anti-PARG antibody (ab169639) at 1 µg/mL

All lanes:

HeLa nuclear extract at 50 µg

Predicted band size: 111 kDa

true

Western blot - Anti-PARG antibody (AB169639)
  • WB

Unknown

Western blot - Anti-PARG antibody (AB169639)

All lanes:

Western blot - Anti-PARG antibody (ab169639) at 1 µg/mL

Lane 1:

PARG-transfected 293T cell lysate at 15 µL

Lane 2:

Non-transfected 293T cell lysate at 15 µL

Predicted band size: 111 kDa

true

Key facts

Host species

Mouse

Clonality

Polyclonal

Isotype

IgG

Carrier free

No

Reacts with

Human

Applications

WB, ICC/IF

applications

Immunogen

Recombinant Full Length Protein corresponding to Human Poly(ADP-ribose) glycohydrolase.

Q86W56

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1 µg/mL", "WB-species-notes": "<p></p>", "ICCIF-species-checked": "testedAndGuaranteed", "ICCIF-species-dilution-info": "10 µg/mL", "ICCIF-species-notes": "<p></p>" }, "Cow": { "WB-species-checked": "predicted", "WB-species-dilution-info": "", "WB-species-notes": "", "ICCIF-species-checked": "predicted", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "" } } }

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.4 Constituents: PBS
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Poly(ADP-ribose) glycohydrolase that degrades poly(ADP-ribose) by hydrolyzing the ribose-ribose bonds present in poly(ADP-ribose) (PubMed : 15450800, PubMed : 21892188, PubMed : 23102699, PubMed : 23474714, PubMed : 33186521, PubMed : 34019811, PubMed : 34321462). PARG acts both as an endo- and exoglycosidase, releasing poly(ADP-ribose) of different length as well as ADP-ribose monomers (PubMed : 23102699, PubMed : 23481255). It is however unable to cleave the ester bond between the terminal ADP-ribose and ADP-ribosylated residues, leaving proteins that are mono-ADP-ribosylated (PubMed : 21892188, PubMed : 23474714, PubMed : 33186521). Poly(ADP-ribose) is synthesized after DNA damage is only present transiently and is rapidly degraded by PARG (PubMed : 23102699, PubMed : 34019811). Required to prevent detrimental accumulation of poly(ADP-ribose) upon prolonged replicative stress, while it is not required for recovery from transient replicative stress (PubMed : 24906880). Responsible for the prevalence of mono-ADP-ribosylated proteins in cells, thanks to its ability to degrade poly(ADP-ribose) without cleaving the terminal protein-ribose bond (PubMed : 33186521). Required for retinoid acid-dependent gene transactivation, probably by removing poly(ADP-ribose) from histone demethylase KDM4D, allowing chromatin derepression at RAR-dependent gene promoters (PubMed : 23102699). Involved in the synthesis of ATP in the nucleus, together with PARP1, NMNAT1 and NUDT5 (PubMed : 27257257). Nuclear ATP generation is required for extensive chromatin remodeling events that are energy-consuming (PubMed : 27257257).
See full target information Poly(ADP-ribose) glycohydrolase

Publications (7)

Recent publications for all applications. Explore the full list and refine your search

Nature communications 15:5822 PubMed38987289

2024

PARG is essential for Polθ-mediated DNA end-joining by removing repressive poly-ADP-ribose marks.

Applications

Unspecified application

Species

Unspecified reactive species

Umeshkumar Vekariya,Leonid Minakhin,Gurushankar Chandramouly,Mrityunjay Tyagi,Tatiana Kent,Katherine Sullivan-Reed,Jessica Atkins,Douglas Ralph,Margaret Nieborowska-Skorska,Anna-Mariya Kukuyan,Hsin-Yao Tang,Richard T Pomerantz,Tomasz Skorski

Cell death & disease 15:150 PubMed38368415

2024

Targeting OGG1 and PARG radiosensitises head and neck cancer cells to high-LET protons through complex DNA damage persistence.

Applications

Unspecified application

Species

Unspecified reactive species

Maria Rita Fabbrizi,Catherine M Nickson,Jonathan R Hughes,Emily A Robinson,Karthik Vaidya,Carlos P Rubbi,Andrzej Kacperek,Helen E Bryant,Thomas Helleday,Jason L Parsons

Cell reports 41:111866 PubMed36543120

2022

The ADP-ribose hydrolase NUDT5 is important for DNA repair.

Applications

Unspecified application

Species

Unspecified reactive species

Hongyun Qi,Roni Helene Grace Wright,Miguel Beato,Brendan D Price

Nature communications 13:187 PubMed35039491

2022

The three-dimensional structure of Epstein-Barr virus genome varies by latency type and is regulated by PARP1 enzymatic activity.

Applications

Unspecified application

Species

Unspecified reactive species

Sarah M Morgan,Hideki Tanizawa,Lisa Beatrice Caruso,Michael Hulse,Andrew Kossenkov,Jozef Madzo,Kelsey Keith,Yinfei Tan,Sarah Boyle,Paul M Lieberman,Italo Tempera

Cancers 13: PubMed34638458

2021

Poly(ADP)-Ribosylation Inhibition: A Promising Approach for Clear Cell Renal Cell Carcinoma Therapy.

Applications

Unspecified application

Species

Unspecified reactive species

Yaroslava Karpova,Danping Guo,Peter Makhov,Adam M Haines,Dmitriy A Markov,Vladimir Kolenko,Alexei V Tulin

Biochemical pharmacology 167:149-162 PubMed30880062

2019

Non-NAD-like PARP-1 inhibitors in prostate cancer treatment.

Applications

Unspecified application

Species

Unspecified reactive species

Yaroslava Karpova,Chao Wu,Ali Divan,Mark E McDonnell,Elizabeth Hewlett,Peter Makhov,John Gordon,Min Ye,Allen B Reitz,Wayne E Childers,Tomasz Skorski,Vladimir Kolenko,Alexei V Tulin

Oncology reports 41:2657-2666 PubMed30864743

2019

PARG regulates the proliferation and differentiation of DCs and T cells via PARP/NF‑κB in tumour metastases of colon carcinoma.

Applications

Unspecified application

Species

Unspecified reactive species

Jie-Qiong Wang,Yi Tang,Qing-Shu Li,Ming Xiao,Ming Li,Yong-Tao Sheng,Yi Yang,Ya-Lan Wang
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com